- FoI Number
- 2024-590
- Subject
- Medications
- Date Received
- 06/01/2025
- Request and Response
-
- Please provide the number of vials used and patients treated for the following products at your trust used in 2024 (total January to December), broken down by brand and size, if possible. If the full-year data is not yet available, please provide the currently available data.
Product
Manufacturer
Size (Units/mg)
Number of vials used (Jan 24-Dec 24)
Number of patients treated
(Jan 24-Dec 24)
Prothrombin Complex Concentrate (PCC)
Beriplex
CSL Behring
500IU 20ml
0
0
1000IU 40ml
0
0
Octaplex
Octapharma
500IU 20ml
0
0
1000IU 40ml
0
0
Prothromplex
Takeda
600IU 17ml
0
0
FEIBA
Takeda
200IU 10ml
0
0
500IU 20ml
0
0
1000IU 40ml
Others (if any please specify)
(if any please specify)
Nil
Nil
Reversal Agents
Ondexxya (andexanet alfa)
Astrazeneca
5x 200 mg
[redacted]
<5
Praxbind (Idaracizumab)
Boehringer Ingelheim
2x 2.5 g
0
0
Fibrinogen Concentrate (FC)
RiaSTAP
CSL Behring
1.0g
FibCLOT
LFB
1.5g
Fibryga
Octapharma
1.0g
Others (if any please specify)
(if any please specify)
Fresh Frozen Plasma (FFP)
Fresh Frozen Plasma
Blood banks
11
<5
Octaplas
Octapharma
0
0
Cryoprecipitate
Cryoprecipitate
Blood banks
<5
<5
Labile Blood Products
Whole blood
Blood banks
n/a
n/a
Red blood cells
Blood banks
401
186
Platelets
Blood banks
13
6
Factor XIII
Fibrogammin
CSL Behring
250IU 4ml
1250IU 20ml
Where we have redacted information or given <5 answers, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
